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ABSTRACT 
 
 
The cannabinoid receptors, members of the G-protein coupled receptor (GPCR) 
superfamily, have been implicated in numerous human physiological functions and 
diseases. These receptors, cannabinoid type 1 (CB1) and cannabinoid type 2 (CB2), are 
most concentrated in the central nervous system and immune cells, respectively, and have 
each become a target of therapeutic interest. Dual CB1/CB2 agonists such as delta-9-
tetrahydrocannbinol (THC) have demonstrated efficacy in the treatment of nausea, pain, 
and glaucoma, but suffer from psychotropic effects mediated by CB1, motivating the search 
for CB2 selective therapeutic agents. Selective modulation of the CB2 receptor has 
therapeutic potential in human health disorders such as pain, inflammation, and cancer. In 
our efforts to develop CB2 receptor selective ligands, we preliminarily examined a structure 
activity relationship (SAR) study of synthetic and natural terpenoid cannabinoids to design 
more potent and selective CB receptor ligands. In an effort to expand this SAR, we 
synthesized a series of analogs with alternative functional groups and substitution patterns 
using a dihydrobenzofuran scaffold, with previous biological assay data guiding the design 
of our new compounds. Aldol condensation and Luche reduction reactions were used to 
create six new analogs. The structures of the new analogs synthesized were confirmed 
using NMR and MS techniques. The compounds were submitted for biological evaluation 
	 v	
in a radioligand displacement assay for both the CB1 and CB2 receptors. One compound 
exhibited modest affinity for the CB2 receptor. The alterations in functional groups and 
substitution patterns provided analog data to help create a more comprehensive structure 
activity relationship study in the future development of CB2 selective compounds. This 
research was funded by Grant Number P20GM104931 from the National Institute of 
General Medical Sciences (NIGMS), COBRE-NPN.  
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INTRODUCTION 
 
 
History and Composition of Cannabis Sativa 
 
 Cannabis sativa, a hemp plant originating in Asia, is one of the oldest known 
mind-altering drug-containing species.1 Historically, the hemp plant has various uses 
including weaving its fibers into fabric, producing bowstrings for archers, and 
manufacturing of paper.2 During the Sufis movement, cannabis use was reported as a 
means of communication with Allah; the founders of this Islamic movement believed this 
was only possible in an ecstatic state.  Thus, as the popularity of the Sufis movement 
increased so did the drug usage. Now some 200-300 million people are estimated to use 
cannabis worldwide1 and in the United States usage may increase due to its legalization 
and availability as a social drug. With such widespread use of cannabis, researchers were 
inclined to study its affects and components to determine its safety and therapeutic 
potential. Thus, since 2012, 545 constituents have been identified with 441 defined as 
non-cannabinoid and 104 as cannabinoids. Eleven types of cannabinoids or 
phytocannabinoids found in the resin and leaves of Cannabis sativa have been classified 
as follows: (-)-delta-9-trans-tetrahydrocannabinol (D9-THC), (-)-delta-8-trans-
tetrahydrocannabinol (D8-THC), cannabigerol (CBG), cannabichromene (CBC), 
cannabidiol (CBD), cannabinodiol (CBND) cannabielsoin (CBE), cannabicyclol (CBL), 
cannabinol (CBN), cannabitriol (CBT) and miscellaneous-type cannabinoids.3 The three 
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main components and more thoroughly researched components of Cannabis sativa are 
CBD, CBN and THC (Figure I).1, 4 
 
Figure I.  Structures of CBD, CBN, and THC 
 
 
 
The Endocannabinoid System 
 
 
The cannabinoid components of cannabis are known to interact with the 
endocannabinoid system, an important and complex signaling system that has regulatory 
roles for cells throughout the nervous, immune, and other systems.5 The endocannabinoid 
system contains two distinct and critical G-protein coupled receptors (GPCRs) described 
as cannabinoid receptor subtype 1 (CB1) and cannabinoid receptor subtype 2 (CB2). 
GCPRs are part of a large protein receptor family which are responsible for signal 
transduction in cells. They contain seven a-helical transmembrane spanning region with 
an extracellular N-terminal and C-terminal cytosolic domain coupled to a G-protein 
comprised of a, b and g subunits. Generally, ligands bind to the receptor causing the 
subsequent detachment of the b and g subunits which activate an effector enzyme. The 
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effector enzyme produces second messengers (e.g. cyclic adenosine monophosphate 
(cAMP), calcium and inositol 1-4-5-triphosphate (IP3)).6 The CB1 and CB2 receptors are 
thought to operate in a more complex manner for signaling which results from the 
inhibition of adenylate cyclase, specific calcium channels, or activation of protein 
kinases. This action modulates neurotransmission.  
 
 
Figure II. Abbreviated neuronal cannabinoid signaling. MAPK = mitogen activated 
protein kinases, AC = adenylyl cyclase, cAMP = cyclic adenosine monophosphate, PKA 
= protein kinase A.7 
 
Both the CB1 and CB2 receptors were cloned in 1991 and 1992 respectively and 
based on their amino acid sequences, were found to be approximately 44% similar 
(Figure II).8 The CB1 receptor is mainly present in central and peripheral neurons, 
however CB2 receptors are more profoundly expressed in the spleen and immune cells.  
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Originally, CB2 receptors were believed to be relatively absent from the brain, but this 
was challenged recently. Researchers have found CB2 protein expression in microglial 
cells in the brain and CB2 expression in neurons.9 However, recent studies7 cast doubt on 
this conclusion due to discrepancies in validation of antibodies used in immunolabeling 
experiments for the CB2 receptor.   
 
 
Figure III. Structure of CB1 and CB2 receptors.10 
 
 
Discovery of the cannabinoid receptors lead researchers to question whether there 
were endogenous ligands linked to these receptors. Later research uncovered the presence 
of endocannabinoids unrelated to the cannabinoid structure found in the hemp plant. 
These ligands were derivatives of polyunsaturated fatty acids and were identified as 
anandamide (N-arachidonoylethanolamide, AEA), 2-arachidonoylglycerol (2-AG), 2-
arachidonylglyceryl ether (noladin ether), O-arachidonyl-ethanolamine (virodhamine) 
	 5	
and N-arachidonoyl-dopamine (NADA).  Anandamide and 2-AG (Figure III) were the 
first ligands discovered and are not produced and stored, but synthesized on demand, then 
subsequently released.11 Anandamide is a partial agonist of CB1 receptor and nearly 
inactive for the CB2 receptor. However, 2-AG is a full agonist of both receptors. 
Interestingly these endocannabinoids also have modest affinity for the vanilloid type-1 
(TRPV1) channel.12 Animal studies have shown that administration of AEA induces 
hypothermia, analgesia, catalepsy, and appetite stimulation.9 Although originally 
considered insignificant initially, 2-AG has been linked to the modulation of feeding, 
hypotension, neuroprotection and cell proliferation and other interesting physiological 
processes.4  
 
Figure IV. Structure of endocannabinoids 2-AG and AEA. 
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Cannabinoid and Endocannabinoid Therapeutic Benefits 
 
 
Although the FDA designation of THC and CBD as Schedule I controlled 
substances may obstruct their development as therapeutics, ample studies have shown 
these cannabinoids have been shown to offer therapeutic advantages in glaucoma, nausea, 
AIDS-associated anorexia and wasting syndrome, multiple sclerosis, chronic pain, 
inflammation and epilepsy.13  Cannabidiol, marketed as Epidiolex® has not been 
approved by the US-FDA but is currently under evaluation in a phase III clinical trial for 
the treatment of seizures in childhood onset epilepsy. In other countries such as Canada 
and the United Kingdom, Nabiximols (Sativex ®) has been approved as a treatment 
option for neuropathic pain and disturbed sleep and spasticity in patients with multiple 
sclerosis. It is administered as an oromucosal spray formulated with THC and CBD 
extracts and is currently in phase III clinical trials in the US. About 2.5 million people 
worldwide are affected by multiple sclerosis and without a cure, management of the 
debilitating symptoms is the goal of treatment.14 However, problems may arise with 
providing patients in the US with this treatment option due to federal regulations of THC 
as a controlled substance. The cannabis extract containing THC is thought to exert its 
therapeutic effects by activation of either CB1 or CB2 receptors.15 However, the 
psychoactive effects of cannabis are thought to be due to THC activating the CB1 
receptor. Therefore, studies shifted to targeting the CB2 receptor to surpass this major 
hurdle by creating ligands that selectively bind to the CB2 receptor. Many studies have 
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proposed that a CB2 agonist may be effective in treating a range of conditions and 
diseases that have a neuro-inflammatory or neurodegenerative component, such as 
multiple sclerosis, amyotrophic lateral sclerosis, Huntington’s disease, and stroke.7,16 
Therefore, our efforts were directed towards the design and synthesis of an agonist with 
selectivity for the CB2 receptor.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 8	
Results and Discussion 
Design and Synthesis of a Benzofuran Scaffold 
My thesis research is a continuation of the graduate dissertation research initially 
conceived by Eric Bow, Ph.D. at the University of Mississippi.  The search for a CB2 
selective modulators began with the design of a scaffold that had spatial similarity to the 
potent THC analog (-)-alpha-10a-hydroxy-delta-9-tetrahydrocannabinol (10a-OH THC), 
a natural product isolated and characterized from Cannabis sativa by Research Scientists 
in COBRE-NPN CORE A (unpublished research).    This naturally occurring 
cannabinoid contains a unique hydroxyl substituent at the 10a-position of THC. The 
analog was found to have high affinity for both the CB1 and CB2 receptors.  10a-OH THC 
was used as a template to create a new scaffold, followed by implementation of a 
structure activity relationships (SAR) study. In order to design CB2 selective analogs, 
several SAR elements derived from the classical cannabinoids (Figure IV) were 
considered, including:  i.) etherification of the phenol to decrease CB1 affinity without 
effecting CB2 binding; ii.) variation of ring sizes and substitution patterns in place of the 
“Northern” cyclohexane ring, and; iii.) substitution in the “Southern” dimethyl pyran 
ring.  
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Figure V. SAR elements of classical cannabinoids. 
 
These features described in conjunction with molecular modeling tools resulted in 
the decision to employ a dihydrobenzofuran scaffold, depicted in Figure VI.6 
Computational superimposition underlined the similarities in interaction areas of the two 
molecules (Figure VII). The furan oxygen and 3-hydroxy group of the 
dihydrobenzofuran scaffold overlapped with the phenol and 10a-hydroxy group of 10a-
OH THC.6 This suggested that this novel scaffold may serve as a viable surrogate of the 
classical cannabinoids and engage in similar binding interactions with CB receptors. 
 
O
OH
H
OH
(a) -10a-OH-D9-THC
O
OH
EWB-5-1  
Figure VI. Structure of (alpha)-10a-OH-delta-9-THC and dihydrobenzofuran 
analog.	
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Figure VII. Computational superimposition of 10a-OH THC and 3-hydroxy-
dihydrobenzofuran. 3D Overlay of 3-hydroxy-dihydrobenzofuran scaffold and 10a-OH 
THC minimized energy structures in Chem3D 15.0 (Perkin-Elmer). Structures of those 
used in simulation are shown left in corresponding colors.6 
 
 
 Using the dihydrobenzofuran scaffold, a series of analogs were proposed in order 
to create a small library of compounds for SAR analysis. Each analog was devised by 
manipulating the “Western half” or “Eastern half” of the 3-hydroxy-dihydrobenzofuran 
or “hydroxyl-aurone” core (Figure VIII). The “Eastern half” was modified by 
experimenting with the addition of various aryl-containing building blocks to the scaffold 
by aldol condensation reactions and subsequent Luche reductions. In addition, the 
“Western half” was altered by changing the nature and position of the alkyl chains. To 
synthesize these modified ligands, an analog with the desired alkyl chain length, thought 
to be optimal for CB receptor binding, was synthesized first. This lead compound was 
then used as a starting point to create several molecules with variations in the phenyl ring 
of the “Eastern half” using a substituted benzaldehyde in an aldol condensation reaction.  
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Figure VIII. Structural map of 3-hydroxy-dihydrobenzofuran scaffold. 
 
Synthesis of benzofuran-3(2H)-one 
Based on Dr. Bow’s synthetic library of compounds synthesized and evaluated for 
CB binding, it was speculated that more potent and selective CB ligands may be realized 
with manipulation of alkyl chain substitution, in particularly the regiochemistry of alkyl 
chain substitution.  As a result, we proposed to synthesize analogs containing alkyl chains 
in the 7 versus the 6 position on the dihydrobenzofuran aromatic ring.  This new 
substituted scaffold would then be subject to subsequent aldol condensation reactions as 
preformed in previous compound synthesis.  
The synthetic protocol for the 7-substituted dihydrobenzofuran scaffold began 
with the nucleophilic addition of n-butyllithium to commercially available 2-
hydroxybenzaldehyde (1), which afforded the desired addition product (2) in high yield 
(Figure IX).  Elimination of the secondary alcohol with catalytic perchloric acid and in 
situ hydrogenation of the resulting styrene gave 2-pentyphenol (3). Friedel-Crafts 
acylation of 3 with chloroacetonitrile under Sugasawa conditions, using BCl3 to direct the 
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acylation ortho to the phenol, afforded the a-chloro ketone (4).  The substitution pattern 
on the aromatic ring of 4 was confirmed by evaluation of the 1H-NMR spectrum. 
Cyclization of 4 was accomplished using potassium carbonate as the base to afford the 
target scaffold 5. 
O
OH
a
OH
OH
b
OH
c
OH
d
O
Cl
O
O
1 2 3 4 5
 
Figure IX. Synthesis of scaffold 4. Reagents and conditions: (a) n-BuLi, THF, 0 oC, 1 h, 
yield: 79.38%. (b) HClO4, Pd/C, H2(g), MeOH, 25 oC, 24 h, yield: 74.47%. (c) 
chloroacetonitrile, BCl3, AlCl3, DCM, 25 oC, 24 h yield: 69.75%. (d) K2CO3, DMF, 25 
oC, 1 h, yield: 51.71%. 
 
The advantages of this synthetic pathway were clear: firstly, scaffold 5 was 
synthesized in 4 reaction steps with an overall yield of 22%. Secondly, the only product 
which required column chromatography purification was the Sugasawa acylation product 
4, and thirdly, analogs of 5 with different alkyl substitutions could be synthesized using 
the same process with alternate nucleophiles or starting material aldehydes. 
With the successful synthesis of the new scaffold 5, we turned our attention to 
analog synthesis. It was envisioned that the final target analogs could be obtained rapidly 
using an aldol condensation reaction followed by selective 1,2-reduction of the resultant 
ketone using Luche reduction conditions (Figure X). 
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Figure X. Synthesis of analogs from 7-pentylbenzofuran-3(2H)-one. Reagents and 
conditions: (i) acetonitrile and ethylenediamine diacetic acid (EDDA), aldehyde building 
block, microwave (1250W power), 2 min. (ii.) NaBH4, CeCl3·7 H2O, methanol or 95% 
ethanol, 25ºC, 20 min. 
 
 
 The aldol condensation reaction of 5 and substituted aldehydes was performed in 
the presence of ethylenediamine acetate (EDDA) under microwave conditions to afford 
benzofuran-3(2H)-ones (6a-b) in reasonable yields. Aqueous workup was not required 
prior to purification, as the crude reaction mixtures are typically viscous oils; simple 
dilution with ethyl acetate and direct loading onto a silica gel column was required for 
purification. 
 The Luche reduction (NaBH4, CeCl3·7 H2O) of benzofuran-3(2H)-ones (6a; R=F) 
resulted in the formation of the desired allyl alcohol (7a).  When benzofuran-3(2H)-one 
6b (R=NHAc) was subjected to the Luche reduction conditions, the allylic alcohol 
product 7b in addition to the rearrangement product 8 was isolated, presumably from the 
nucleophilic addition of ethanol to the exo-methylene of 6b via an SN2’ mechanism.  
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 One additional set of analogs were also synthesized from the 6-pentylbenzofuran-
3(2H)-one scaffold 9 previously synthesized by Dr. Eric Bow in the Rimoldi lab.  Briefly, 
compound 9 was subjected to the aldol condensation with 4-methoxybezaldehye under 
microwave heating to afford condensation product 10.  Luche reduction of 10 using 95% 
ethanol as the solvent afforded a mixture of products (11a and 11b) in modest yields. 
 
 
Figure XI. Synthesis of analogs from 6-pentylbenzofuran-3(2H)-one (9). Reagents and 
conditions: (i) acetonitrile and ethylenediamine diacetic acid (EDDA), 4-
methoxybezaldehye, microwave (1250W power), 2 min. (ii.) NaBH4, CeCl3·7 H2O, 
methanol or 95% ethanol, 25ºC, 20 min. 
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Materials and Methods 
 
General Methods 
 
 All reactions were monitored for starting material consumption or product 
formation using thin-layer chromatography (TLC) techniques and visualized under UV 
light (254 nM) or stained with ethanolic p-anisaldehyde, potassium permanganate or 
phosphomolybdic acid.   Reactants, reagents, and solvents were purchased from 
Reactions performed under “standard anhydrous conditions” refers to reactions that 
employed flame-dried glassware evacuated and purged with an inert blanket of argon, 
and using commercially available anhydrous solvents.  Low resolution molecular weight 
analysis was preformed using a Waters Micromass ZQ single quadrupole mass 
spectrometer with either positive (ESI+) or negative (ESI-) electrospray ionization. A 
Bruker 400 MHz Avance Nuclear Magnetic Resonance (NMR) spectrometer was used to 
acquire proton (1H) and carbon (13C) NMR spectral data, and the data processed using 
MNova (MestReNova) software. Ligands were assessed for putative receptor affinity 
using a cannabinoid receptor binding assay conducted by COBRE Core C at the 
University of Mississippi. The analogs synthesized were tested in three solutions of 
differing concentrations (0.5 µM, 2.5 µM, 10 µM) and run in a competitive radioligand 
binding assay against both the CB1 and CB2 receptors. The percent displacement of the 
compounds was calculated by considering both the binding of the analog (specific 
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binding) and the nonspecific binding using the following formula: 100-(binding of 
compound – nonspecific binding) x (100/specific binding).4 
 
Experimental Methods 
 
(2)  2-(1-hydroxypentyl)phenol 
 Under standard anhydrous conditions, commercially available 2-
hydroxy-benzaldehyde (1, 872.6 µL, 8.19 mmol) was dissolved in 
THF (15 mL) and cooled to 0°C.  n-Butyllithium (1 mL, 16.38 
mmol) was slowly added dropwise to the solution. The reaction stirred for one hour, and 
the solution was diluted with diethyl ether, and quenched carefully with methanol (2 mL). 
Water was added and the reaction mixture was placed in a separatory funnel and 
extracted 3x with 20 mL of ethyl acetate.  The organic layers were combined and washed 
with water and brine. The organic layer was dried over magnesium sulfate and 
concentrated in vacuo to give 1.17g (79.38%) of 2.   MS (ESI+) m/z = 203.28 [M+Na]+. 
1H NMR (400 MHz, CDCl3) δ 8.12 (s, 1H), 7.16 (t, J = 7.7 Hz, 1H), 6.94 (d, J = 7.5 Hz, 
1H), 6.84 (q, J = 7.1 Hz, 2H), 4.80 (t, J = 6.6 Hz, 1H), 3.16 (s, 1H), 1.97 – 1.72 (m, 2H), 
1.31 (ddd, J = 34.3, 11.4, 4.4 Hz, 4H), 0.91 (t, J = 6.1 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 155.37, 128.72, 127.70, 127.20, 119.68, 117.01, 76.00, 36.90, 27.88, 22.48, 
13.98. 
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(3)    2-pentylphenol 
 5% Pd/C (100 mg) and 60 mL of methanol were added to 
separate Erlenmeyer flasks.  30 mL of methanol was poured 
into the flask containing the Pd/C and then transferred to a 
round-bottomed flask containing compound 2 (1.17g, 6.50 mmol) and repeated with the 
remaining 30 mL of methanol. Three drops of perchloric acid was added to the mixture 
and stirring was initiated. The reaction flask was then purged of air and subsequently 
saturated with hydrogen gas. After 24 hours, the reaction was halted by filtration of the 
Pd/C, rinsing the catalyst repeatedly with methanol, and concentrating in vacuo until 
approximately 90% of the methanol was evaporated. The product was extracted with 
ethyl acetate, washed with brine, dried over magnesium sulfate, and concentrated in 
vacuo to give 1.07 g (74.49%) of 3. 1H NMR (400 MHz, CDCl3) δ 7.19 (d, J = 7.4 Hz, 
1H), 7.13 (t, J = 7.7 Hz, 1H), 6.93 (t, J = 7.4 Hz, 1H), 6.83 (d, J = 7.9 Hz, 1H), 5.78 (s, 
1H), 2.75 – 2.61 (m, 2H), 1.70 (p, J = 7.4 Hz, 2H), 1.47 – 1.37 (m, 4H), 0.98 (t, J = 6.4 
Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 172.37, 153.68, 130.18, 128.98, 126.92, 120.60, 
115.27, 77.46, 77.14, 76.82, 60.97, 31.81, 29.99, 29.56, 22.65, 21.09, 14.13, 14.08. 
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(4)    2-chloro-1-(2-hydroxy-3-pentylphenyl)ethan-1-one 
Compound 3 (795.30 mg, 4.87 mmol) was dissolved in 5 
mL of anhydrous dichloromethane (DCM). Boron 
trichloride (680.08 mg, 5.80 mmol) was added to a 
separate round-bottomed flask, cooled to 0 oC, and the prepared solution of compound 3, 
chloroacetonitrile (438.67 mg, 5.81 mmol), and aluminum trichloride (322.28 mg, 
2.42mmol) were added successively.  The reaction was allowed to warm to room 
temperature and stirred for 24 hours. The reaction was neutralized with 30 mL of 2 N 
hydrochloric acid and allowed to stir for one hour. The organic phase was extracted with 
DCM, dried over magnesium sulfate and concentrated in vacuo. Silica gel column 
chromatography purification (20% ethyl acetate/hexanes) yielded 813.0 mg (69.32%) of 
4. MS (ESI+) m/z = 263.08 [M+Na]+. 1H NMR (400 MHz, CDCl3) δ 12.01 (s, 1H), 7.55 
(dd, J = 8.1, 1.5 Hz, 1H), 7.46 – 7.35 (m, 1H), 6.92 – 6.82 (m, 1H), 4.74 (s, 2H), 2.73 – 
2.62 (m, 2H), 1.69 – 1.59 (m, 2H), 1.35 (dt, J = 7.3, 3.8 Hz, 4H), 0.96 – 0.83 (m, 3H). 13C 
NMR (101 MHz, CDCl3) δ 137.30, 136.39, 132.76, 127.08, 118.72, 63.59, 45.43, 31.67, 
29.47, 28.97, 22.53, 14.03. 
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(5)   7-pentylbenzofuran-3(2H)-one 
Compound 4 (813.0 mg, 3.38 mmol) and potassium carbonate (933.0 
mg, 6.75 mmol) were added to 10 mL of anhydrous DMF. After 3 
hours, the reaction was diluted with water and extracted with ethyl 
acetate and washed with water and brine. The organic phase was dried 
over magnesium sulfate and concentrated in vacuo. Silica gel column 
chromatography purification (20% ethyl acetate/hexanes) yielded 356.70 mg (51.71%) of 
5. MS (ESI+) m/z = 227.11 [M+Na]+. 1H NMR (400 MHz, CDCl3) δ 7.50 (d, J = 7.7 Hz, 
1H), 7.42 (d, J = 7.2 Hz, 1H), 7.01 (t, J = 7.5 Hz, 1H), 4.62 (s, 2H), 2.72 – 2.62 (m, 2H), 
1.66 (dt, J = 13.7, 8.3 Hz, 3H), 1.36 (dt, J = 7.0, 4.3 Hz, 5H), 0.91 (t, J = 5.6 Hz, 4H). 13C 
NMR (101 MHz, CDCl3) δ 200.56, 172.61, 137.38, 128.72, 121.92, 121.30, 120.67, 
74.60, 31.52, 29.06, 28.68, 22.46, 14.01. 
 
General Procedure A: Aldol Condensations 
 Scaffold 5 or 9 (25.0 mg) was added to a glass vial with 1 equivalent of 
desired benzaldehyde and 1 equivalent of ethylenediamine diacetic acid (EDDA), 
dissolved in 2 mL acetonitrile (ACN). The vial was then microwaved at 50% power 
(1250W) for 2 minutes followed by an additional 30-60 seconds, if necessary, to ensure 
consumption of starting material by TLC.  The reaction was then purified using silica gel 
column chromatography.  
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General Procedure B:  Luche Reductions 
 The purified aldol condensation product was dissolved in either methanol 
or 95% ethanol and was subsequently combined with 1.1 equivalents of cerium (III) 
chloride heptahydrate and chilled to 0°C.  1.1 equivalent of sodium borohydride was 
added slowly to the solution in equal portions. The reaction was quenched slowly with 
water and extracted using ethyl acetate. The organic phase was washed with brine and 
dried over magnesium sulfate, and concentrated in vacuo. The crude product was purified 
using silica gel column chromatography (ethyl acetate/hexanes mobile phase). 
 
(6a)    (Z)-2-(4-fluorobenzylidene)-7-pentylbenzofuran-3(2H)-one 
 
Synthesized using General Procedure A and 1 equivalent of 4-
fluorobenzaldehyde.  Yield: 73.71% MS (ESI+) m/z = 333.32 
[M+Na]+. 1H NMR (400 MHz, CD3CN) δ 8.06 – 7.91 (m, 2H), 
7.57 (d, J = 7.4 Hz, 2H), 7.22 (dt, J = 15.2, 8.2 Hz, 3H), 6.82 (s, 
1H), 2.90 – 2.80 (m, 2H),1.81 – 1.69 (m, 2H), 1.45 – 1.34 (m, 5H), 0.93 (t, = 7.0 Hz, 4H). 
13C NMR (101 MHz, CD3CN) δ 184.50, 164.45, 146.66, 137.13, 133.54, 133.46, 128.03, 
123.70, 121.45, 116.09, 115.87, 110.36, 31.20, 29.03, 28.34, 22.14, 13.32. 
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(7a)  (Z)-2-(4-fluorobenzylidene)-7-pentyl-2,3-dihydrobenzofuran-3-ol 
Synthesized using General Procedure B and 95% ethanol as solvent. 
Yield: 46.86% MS (ESI+) m/z = 335.29 [M+Na]+. 1H NMR (400 
MHz, CDCl3) δ 7.71 (dd, J = 8.5, 5.7 Hz, 2H), 7.34 (d, J = 7.3 Hz, 
1H), 7.18 (d, J = 7.5 Hz, 1H), 7.06 (dt, J = 18.8, 8.1 Hz, 4H), 5.98 
(s, 1H), 5.76 (s, 1H), 2.78 – 2.71 (m, 2H), 1.73 (q, J = 7.1 Hz, 3H), 1.45 – 1.39 (m, 4H), 
0.95 (t, J = 6.8 Hz, 4H). 13C NMR (101 MHz, CDCl3) δ 162.68, 156.67, 155.81, 130.91, 
130.17, 130.09, 126.35, 125.71, 122.92, 122.90, 115.44, 115.23, 104.60, 72.83, 31.66, 
29.76, 29.28, 22.46, 14.06. 
 
(6b)   (Z)-N-(4-((3-oxo-7-pentylbenzofuran-2(3H)ylidene)methyl)phenyl)acetamide 
Synthesized using General Procedure A and 1 equivalent of 4-
acetamindobenzaldehyde.  Yield: 69.44% MS (ESI+) m/z = 
372.33 [M+Na]+. 1H NMR (400 MHz, CDCl3) δ 7.71 (d, J = 
8.3 Hz, 2H), 7.57 (d, J = 7.8 Hz, 2H), 7.43 (d, J = 7.4 Hz, 1H), 
7.30 (d, J = 7.0 Hz, 1H), 6.97 (t, J = 7.3 Hz, 1H), 6.67 (s, 1H), 5.18 (s, 2H), 2.67 (t, J = 
7.4 Hz, 2H), 2.05 (s, 3H), 1.61 (s, 2H), 1.25 (s, 4H), 0.76 (t, J = 5.9 Hz, 3H). 13C NMR 
(101 MHz, CDCl3) δ 207.07, 164.23, 146.22, 140.18, 136.58, 132.25, 127.66, 123.22, 
121.58, 121.11, 119.49, 112.46, 53.41, 31.34, 28.95, 28.72, 24.23, 22.24, 13.80. 
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(7b)   (Z)-N-(4-((3-hydroxy-7-pentylbenzofuran-2(3H)-ylidene)methyl)phenyl)acetamide 
Synthesized using General Procedure B and methanol as 
solvent. Yield: 14.49% MS (ESI+) m/z = 374.37 [M+Na]+. 1H 
NMR (400 MHz, CDCl3) δ 7.54 (d, J = 3.3 Hz, 4H), 7.33 (d, J 
= 7.4 Hz, 1H), 7.08 (dd, J = 17.2, 7.4 Hz, 2H), 6.52 (s, 1H), 
5.66 (s, 1H), 2.86 (t, J = 6.8 Hz, 2H), 2.18 (s, 4H), 1.78 – 1.70 (m, 2H), 1.40 – 1.32 (m, 
5H), 0.89 (t, J = 6.7 Hz, 4H). 
 
(8)    N-(4-(ethoxy(7-pentylbenzofuran-2-yl)methyl)phenyl)acetamide 
Synthesized using General Procedure B and 95% ethanol as 
solvent. Yield: 32.26% MS (ESI+) m/z = 402.71 [M+Na]+. 
1H NMR (400 MHz, CDCl3) δ 7.64 (s, 1H), 7.52 (d, J =8.5 
Hz, 2H), 7.44 (d, J = 8.4 Hz, 2H), 7.38 – 7.31 (m, 1H), 7.12 
(d, J = 7.4 Hz, 1H), 7.06 (d, J =7.2 Hz, 1H), 6.53 (s, 1H), 5.49 (s, 1H), 3.72 – 3.56 (m, 
2H), 3.49 (s, 1H), 2.87 (t, J = 7.4 Hz, 2H), 2.16 (s, 3H), 1.72 (p, J = 7.3 Hz, 3H), 1.34 (dt, 
J = 7.0, 3.8 Hz, 5H), 1.32 – 1.25 (m, 4H), 0.90 (t, J = 5.6 Hz, 4H). 13C NMR (101 MHz, 
CDCl3) δ 168.54, 156.95, 153.87, 137.75, 135.20, 127.93, 127.65, 126.51, 124.07, 
122.72, 119.79, 118.45, 104.85, 77.37, 77.06, 76.74, 64.97, 31.59, 29.62,29.38, 24.51, 
22.49, 15.30, 14.01. 
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(10)      (Z)-2-(4-methoxybenzylidene)-6-pentylbenzofuran-3(2H)-one 
Synthesized using General Procedure A, scaffold 9, and 1 
equivalent of 4-methoxybenzaldehyde. Yield: 35.69% 
MS (ESI+) m/z = 345.51 [M+Na]+. 1H NMR (400 MHz, 
CDCl3) δ 7.87 (d, J = 8.9 Hz, 2H), 7.69 (d, J = 7.8 Hz, 1H), 7.13 (s, 1H), 7.02 (d, J = 8.9 
Hz, 1H), 6.97 (d, J = 8.9 Hz, 2H), 6.84 (s, 1H), 3.86 (s, 3H), 2.79 – 2.67 (m, 2H), 1.67 (t, 
J = 11.2 Hz, 2H), 1.35 (dt, J = 7.6, 3.8 Hz, 5H), 0.94 – 0.87 (m, 3H). 13C NMR (101 
MHz, CDCl3) δ 184.15, 166.40, 160.89, 153.68, 146.36, 133.26, 125.18, 124.18, 124.09, 
119.72, 114.43, 112.79, 112.29, 55.35, 36.79, 31.37, 30.67, 22.48, 14.19, 13.97. 
 
(11a)      (Z)-2-(4-methoxybenzylidene)-6-pentyl-2,3-dihydrobenzofuran-3-ol 
Synthesized using General Procedure B and 95% ethanol 
as solvent. Yield: 5.28% MS (ESI+) m/z = 347.43 
[M+Na]+. 1H NMR (400 MHz, CDCl3) δ 7.42 (dd, J = 
8.2, 4.5 Hz, 3H), 7.28 (s, 1H), 7.05 (d, J = 8.7 Hz, 1H), 6.94 (d, J = 8.6 Hz, 2H), 6.49 (s, 
1H), 5.91 (s, 1H), 3.84 (s, 3H), 2.76 – 2.67 (m, 2H), 1.66 (dt, J = 15.1, 7.5 Hz, 3H), 1.43 
– 1.31 (m, 5H), 0.91 (t, J = 6.8 Hz, 4H). 
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(11b)   2-(ethoxy(4-methoxyphenyl)methyl)-6-pentylbenzofuran 
Synthesized using General Procedure B and 95% ethanol 
as solvent. Yield: 17.21% MS (ESI+) m/z = 375.42 
[M+Na]+. 1H NMR (400 MHz, CDCl3) δ 7.45 – 7.36 (m, 
3H), 7.03 (dd, J = 7.9, 1.3 Hz, 1H), 6.92 (d, J = 8.8 Hz, 2H), 6.50 (s, 1H), 5.46 (s, 1H), 
3.83 (s, 3H), 3.70 –3.54 (m, 2H), 2.74 – 2.63 (m, 2H), 1.65 (dt, J = 15.0, 7.5 Hz, 2H), 
1.38 – 1.32 (m, 3H), 1.30 (t, J= 7.0 Hz, 5H), 0.90 (t, J = 6.9 Hz, 4H). 13C NMR (101 
MHz, CDCl3) δ 159.43, 157.14, 155.58, 139.54, 131.38, 128.54, 125.72, 123.48, 120.39, 
113.82, 110.97, 104.41, 77.26, 64.76, 55.28, 36.08, 31.52, 31.40, 22.55, 15.29, 14.02. 
 
Biological Evaluation (COBRE-NPN CORE C) 
 Cannabinoid receptor assay were conducted by COBRE Core C at The 
University of Mississippi. Assays were conducted in accordance with the method 
republished below in Tarawneh et al. "Reprinted with permission from Tarawneh, A. et 
al., Flavonoids from Perovskia atriplicifolia and Their in Vitro Displacement of the 
Respective Radioligands for Human Opioid and Cannabinoid Receptors. Journal of 
Natural Products, 2015. 78(6): p. 1461. Copyright (2015) American Chemical Society." 
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Cell Culture and Membrane Preparation. 
 HEK293 cells (ATCC) were stably transfected with plasmids containing 
cloned humancannabinoid receptor subtypes 1 and 2 (obtained from Origene, Rockville, 
MD, USA). These cells were maintained in a humidified incubator at 37°C and 5% CO2 
in a Dulbecco’s modified Eagle’s medium (DMEM) nutrient mixture F-12 HAM 
supplemented with 2 mM L-glutamine, 10% fetal bovine serum, 1000 IU/mL penicillin, 
and 1000 µg/mL of streptomycin, and 0.5 mg/mL G418 antibiotic solution. Membranes 
for the radioligand binding assays were prepared by scraping the cells in cold Tris-HCl, 
pH 7.4, and then centrifuged at 5200 g for 10 min at 4°C. The supernatant was discarded, 
and the pellet was resuspended in the same buffer, homogenized using a sonic dis-
membrator model 100 (Fisher Scientific, Pittsburgh, PA, USA) for 30 seconds, and then 
centrifuged at 1000g for 10 min at 4°C. The supernatant was saved, and the pellet 
underwent the suspension and sonication process two additional times under the same 
conditions. The supernatants were combined and centrifuged at 23300g for 40 minutes at 
4°C. The pellet was resuspended and aliquoted into 2 mL vials and stored at −80 °C. The 
total protein concentration was determined using a Pierce BCA protein assay kit (Thermo 
Scientific, Rockford, IL, USA) according to the manufacturer’s instructions. The optimal 
membrane and radioligand concentrations for each receptor batch were established 
through membrane evaluation and saturation binding experiments.  
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Radioligand Displacement Assay for Cannabinoid Receptor Subtypes. 
 Compounds evaluated in this assay were run in competition binding with 
both cannabinoid receptor subtypes, CB1 and CB2. CB receptor binding screening was 
performed under the following conditions: 10 µM of each compound from independent 
triplicate dilutions was incubated with 1.6975 nM (CB1) or 1.959 nM (CB2). [3H]-CP 
55,940, and 5 µg of CB1 or 1 µg of CB2 membrane were incubated for 90 min at 37°C 
with gentle agitation in a 96-well plate in a 0.2 mL final volume of 50 mM Tris-HCl, 20 
mM EDTA, 154 mM NaCl, and 0.2% radioimmunoassay grade BSA, pH 7.4. The 
reaction was terminated via rapid vacuum filtration through a UniFilter 96 GF/C filter 
(PerkinElmer Life Sciences Inc., Boston, MA, USA), presoaked with 0.3% 
polyethylenimine, followed by 10 washes with 50 mM Tris-HCl, pH 7.4, buffer 
containing 0.2% BSA. Filters were dried, 25 µL of MicroScint20 was added, and the 
plates were read using a TopCount NXT microplate scintillation counter (PerkinElmer 
Life Sciences Inc., Boston, MA, USA). Total binding was defined as binding in the 
presence of vehicle (1.0% DMSO). Nonspecific binding was the binding observed in the 
presence of 10.0 µM CP-55,940. Specific binding was defined as the difference between 
total and nonspecific binding. Percent displacement was calculated using the following 
formula: 100-(binding of compound – nonspecific binding) x (100/specific binding). 
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Results 
 Three target analogs were successfully synthesized from the 7-
pentylbenzofuran-3(2H)-one (5), namely the (Z)-2-benzylidene-7-pentyl-2,3-
dihydrobenzofuran-3-ols (7a and 7b) and the rearrangement product 8.   Two additional 
analogs containing a 4-methoxyphenyl group (11a and 11b), and were synthesized from 
6-pentylbenzofuran-3(2H)-one (9) (Figure XII).  The facile synthesis of these scaffolds 
allowed for the implementation of an aldol condensation reaction, performed under 
microwave heating, and the Luche reduction reaction, which resulted in some instances, 
rearrangement products containing ethanol adducts. The Luche reduction of 10 was 
unique insofar as it resulted in sufficient yields of both the allylic alcohol product and 
rearrangement product for testing.   The structures of the final products and intermediates 
were confirmed using NMR spectrometry.  
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Figure XII. Series of synthesized ligands subjected to CB binding assay. 
 
 
 
 
 
 CB1 % Displacement CB2 % Displacement 
 10 µM 2.5 µM 0.5 µM 10 µM 2.5 µM 0.5 µM 
7a 24.3 17.6 14.8 43.3 30.5 14.0 
8 59.0 44.9 37.7 83.4 62.2 26.3 
7b 0 13.0 15.2 20.1 15.2 15.8 
11a 57.1 38.0 37.7 68.9 48.8 32.0 
11b 71.9 57.0 36.8 79.6 78.9 56.2 
Table I. CB binding data 
 
 
 CB binding assay data results demonstrated that compound 11b had the highest 
affinity of the five compounds tested (at 500 nM concentration).  Both 4-methoxyphenyl 
derivatives derived from the 6-pentyl substituted scaffold, 11a and 11b displayed better 
binding affinity with a slight selectivity for the CB2 receptor, more so than with ethoxy 
rearrangement.  Compared to previously tested compound (3.4), compounds 7b and 8 did 
not bind as effectively, suggesting that 7-substitued alkyl chains have a higher 
affinity/better fit for both CB receptors. However, 7b and 8 seem to favor binding to the 
CB2 receptor in higher concentrations.  In addition, the allylic alcohol product seems to 
be the least favorable structure for binding affinity (Table II).  
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 CB1 % Displacement CB2 % Displacement 
 10 uM 2.5 uM 0.5 uM 10 uM 2.5 uM 0.5 uM 
 
3.44 
94.5 * 31.9 96.7 * 57.7 
 
8 
59.0 44.9 37.7 83.4 62.2 26.3 
 
7b 
- 13.0 15.2 20.1 15.2 15.8 
Table II. Comparison of CB receptor assay binding for compounds 7b, 8 and 3.4 
(synthsized by Eric Bow). * = not tested in corresponding concentration. - = 0% 
displacement.  
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 Based on the CB receptor binding data, the analog containing the 4-methoxyphenyl 
group in addition to the ethoxy rearrangement (11b) has the greatest potential for CB2 
selectivity.  The location of the pentyl chain has an influence on CB binding and 
selectivity, with 6-alkyl substitution preferred over 7-alkyl substitution.  Additional 
analogs will be required to build a more complete structure activity relationship analysis.  
Although the compound data did not result in the discovery of a CB2 selective compound, 
they were very promising and offered a direction for future work towards the discovery 
of CB2 selective ligands.  
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